RDAA, an #oncogenicdriver in non-mutated #NSCLC, demonstrates strong sensitivity to #FDA-approved #ALKinhibitors, highlighting a promising therapy option for patients lacking #TyrosineKinase mutations. @mdanderson.bsky.social

#STTT #OpenAccess: doi.org/10.1038/s413...